IRADIMED CORPORATION reports results for the quarter ended September 30 - Earnings Summary

What happened

IRADIMED reported quarterly adjusted earnings of 55 cents per share, matching analyst expectations, and revenue of $24.20 million, up 14.2% from a year ago. Quarterly net income was $6.51 million.

Confirmed

Global impact / market context

Matching the 55-cent profit estimate while beating the $23.47 million revenue estimate shows sales growth with stable profit per share. That mix matters because rising revenue can support future profit if costs stay controlled.

Analyst inference

Analysts rate the stock a buy, with 2 buy, 1 hold and no sell ratings. The median 12-month price target is $118.00, about 27.3% above the last closing price of $85.74, which suggests analysts see room for gains.

Confirmed

What to watch

1. Watch whether revenue keeps growing at a double-digit pace and whether profit per share stays near 55 cents, since both matched or beat analyst expectations. Confirmed
2. Watch for future analyst rating changes or price target updates, because the current buy rating and $118.00 target may be revised after results. Proposed
3. Watch whether the stock recovers from its 11.9% year-to-date decline, since continued sales growth could shift investor confidence. Analyst inference

Evidence

• Original source link unavailable